ATE220331T1 - Cd40 bindendes protein zur stimulierung der immunantwort - Google Patents

Cd40 bindendes protein zur stimulierung der immunantwort

Info

Publication number
ATE220331T1
ATE220331T1 AT96909555T AT96909555T ATE220331T1 AT E220331 T1 ATE220331 T1 AT E220331T1 AT 96909555 T AT96909555 T AT 96909555T AT 96909555 T AT96909555 T AT 96909555T AT E220331 T1 ATE220331 T1 AT E220331T1
Authority
AT
Austria
Prior art keywords
immune response
binding protein
stimulate
individuals
pathogenic
Prior art date
Application number
AT96909555T
Other languages
English (en)
Inventor
Mark Alderson
Kim A Campbell
Mary K Kennedy
Charles R Maliszewski
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE220331T1 publication Critical patent/ATE220331T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT96909555T 1995-03-01 1996-02-29 Cd40 bindendes protein zur stimulierung der immunantwort ATE220331T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39623095A 1995-03-01 1995-03-01
PCT/US1996/002839 WO1996026735A1 (en) 1995-03-01 1996-02-29 Method for stimulating an immune response

Publications (1)

Publication Number Publication Date
ATE220331T1 true ATE220331T1 (de) 2002-07-15

Family

ID=23566398

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96909555T ATE220331T1 (de) 1995-03-01 1996-02-29 Cd40 bindendes protein zur stimulierung der immunantwort

Country Status (15)

Country Link
EP (1) EP0812206B1 (de)
JP (1) JP3657271B2 (de)
KR (1) KR19980702490A (de)
AT (1) ATE220331T1 (de)
AU (1) AU699291B2 (de)
CA (1) CA2213798C (de)
DE (1) DE69622259T2 (de)
DK (1) DK0812206T3 (de)
ES (1) ES2179187T3 (de)
FI (1) FI973484A7 (de)
MX (1) MX9706588A (de)
NO (1) NO973875L (de)
NZ (1) NZ305083A (de)
PT (1) PT812206E (de)
WO (1) WO1996026735A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999022008A1 (en) * 1997-10-27 1999-05-06 Sumitomo Electric Industries, Ltd. Inducer for production of antigen-specific antibody, expression vector containing gene therefor, and method of inducing production of antigen-specific antibody
AU2004199A (en) * 1997-12-19 1999-07-12 Immunex Corporation Method for reducing susceptibility to hiv infection
ES2330017T3 (es) * 1998-05-23 2009-12-03 Leiden University Medical Center Ligandos de cd40 y peptidos de ctl para tratar tumores.
US7371392B2 (en) 2000-02-02 2008-05-13 The United States Of America As Represented By The Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus
KR101460551B1 (ko) 2006-09-18 2014-11-18 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역 반응을 향상시키는 조성물 및 방법
AU2008318615A1 (en) 2007-10-30 2009-05-07 Texas A&M University System Compositions and methods of enhancing immune responses to flagellated bacterium
CA2704422C (en) 2007-11-01 2019-09-24 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to eimeria
DK2525817T3 (en) 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
NZ604412A (en) 2010-06-09 2015-01-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
JP6125489B2 (ja) 2011-04-29 2017-05-10 アペクシジェン， インコーポレイテッド 抗ｃｄ４０抗体および使用方法
DK2914627T3 (da) 2012-10-30 2021-07-12 Apexigen Inc Anti-cd40-antistoffer og fremgangsmåder til anvendelse
EA030929B1 (ru) 2013-02-14 2018-10-31 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас КОМПОЗИЦИИ И СПОСОБЫ УСИЛЕНИЯ ИММУННЫХ ОТВЕТОВ НА Eimeria ИЛИ ОГРАНИЧЕНИЯ ИНФЕКЦИИ Eimeria
HK1219045A1 (zh) 2013-03-15 2017-03-24 The Board Of Trustees Of The University Of Arkansas 增强对肠道病原体免疫应答的组合物和方法
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
EP3445783A2 (de) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistische antikörper zur bindung von humanem cd40 und verwendungen davon
BR112018072592A2 (pt) 2016-05-03 2019-04-16 The Board Of Trustees Of The University Of Arkansas vetor de vacina de levedura que inclui polipeptídeos imunoestimulantes e antigênicos, e métodos de uso dos mesmos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100283541B1 (ko) * 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
DK0724456T3 (da) * 1993-10-01 2004-04-13 Immunex Corp CD40-Antistoffer

Also Published As

Publication number Publication date
ES2179187T3 (es) 2003-01-16
DK0812206T3 (da) 2002-09-09
AU5301196A (en) 1996-09-18
DE69622259T2 (de) 2003-03-27
MX9706588A (es) 1997-11-29
JPH11506418A (ja) 1999-06-08
NO973875D0 (no) 1997-08-22
FI973484L (fi) 1997-10-24
EP0812206B1 (de) 2002-07-10
PT812206E (pt) 2002-11-29
CA2213798C (en) 2001-02-06
JP3657271B2 (ja) 2005-06-08
FI973484A7 (fi) 1997-10-24
DE69622259D1 (de) 2002-08-14
FI973484A0 (fi) 1997-08-25
NZ305083A (en) 1999-06-29
KR19980702490A (ko) 1998-07-15
NO973875L (no) 1997-10-31
WO1996026735A1 (en) 1996-09-06
EP0812206A1 (de) 1997-12-17
AU699291B2 (en) 1998-11-26
CA2213798A1 (en) 1996-09-06

Similar Documents

Publication Publication Date Title
ATE220331T1 (de) Cd40 bindendes protein zur stimulierung der immunantwort
ATE163195T1 (de) Lösliche liganden für cd40
NO963168L (no) Immunstimulatoriske monoklonale antistoffer
DK0724456T3 (da) CD40-Antistoffer
HUP9901874A2 (hu) Humán TNFalfa-t kötő antitestek
DE69129989D1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
ATE245030T1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
DE50114906D1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
NO971059D0 (no) Modifiserte human-C3-proteiner
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
DE60109359D1 (de) Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten
DE69803392D1 (de) Anti-cd40l immunotoxine zur behandlung von krankheiten
DE59611293D1 (de) Protein mit dnase-aktivität
ATE136469T1 (de) Neue verwendung eines monoklonalen antikörpers
MX9602274A (es) Procedimiento para la preservacion de antigenos sin usar inhibidores enzimaticos y su aplicacion en metodos inmunologicos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee